CoChat
Sign Up
Cited by 263Neuroscience and Neuropharmacology ResearchAmino Acid Enzymes and MetabolismReceptor Mechanisms and Signaling

The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.

Influence of GluN2 subunit identity on NMDA receptor function

Open access
Wyllie, D.J.A., Livesey, M.R., Hardingham, G.E.·2013·Neuropharmacology
DOI 10.1016/j.neuropharm.2013.01.016PMC PMC3778433
Open this paper in CoChat — free accountOpen PDF

Abstract

N-methyl-d-aspartate receptors (NMDARs) are ligand-gated ion channels ('ionotropic' receptors) activated by the major excitatory neurotransmitter, l-glutamate. While the term 'the NMDAR' is often used it obscures the fact that this class of receptor contains within it members whose properties are as different as they are similar. This heterogeneity was evident from early electrophysiological, pharmacological and biochemical assessments of the functional properties of NMDARs and while the molecular basis of this heterogeneity has taken many years to elucidate, it indicated from the outset that the diversity of NMDAR phenotypes could allow this receptor family to subserve a variety of functions in the mammalian central nervous system. In this review we highlight some recent studies that have identified structural elements within GluN2 subunits that contribute to the heterogeneous biophysical properties of NMDARs, consider why some recently described novel pharmacological tools may permit better identification of native NMDAR subtypes, examine the evidence that NMDAR subtypes differentially contribute to the induction of long-term potentiation and long-term depression and discuss how through the use of chimeric proteins additional insights have been obtained that account for NMDAR subtype-dependency of physiological and pathophysiological signalling. This article is part of the Special Issue entitled 'Glutamate Receptor-Dependent Synaptic Plasticity'.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2013.01.016

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The identity of the GluN2 subunit controls pharmacological and biophysical properties of NMDARs. Schematic representation of each of the four di-heteromeric NMDARs with the GluN1 subunits indicated in grey. Agonist and co-agonist potency is lowest at GluN1/GluN2A NMDARs and highest at GluN1/GluN2D NMDARs. Deactivation rates are fastest for GluN2A-containing NMDARs and slowest for NMDARs containing GluN2D subunits. GluN2B- and GluN2C-containing NMDARs show approximately similar deactivation rates. NMDARs fall into two categories (GluN2A/B-like and GluN2C/D-like) when considering voltage-dependent block by Mg2+, permeability to Ca2+ and unitary conductance.
Fig. 1 The identity of the GluN2 subunit controls pharmacological and biophysical properties of NMDARs. Schematic representation of each of the four di-heteromeric NMDARs with the GluN1 subunits indicated in grey. Agonist and co-agonist potency is lowest at GluN1/GluN2A NMDARs and highest at GluN1/GluN2D NMDARs. Deactivation rates are fastest for GluN2A-containing NMDARs and slowest for NMDARs containing GluN2D subunits. GluN2B- and GluN2C-containing NMDARs show approximately similar deactivation rates. NMDARs fall into two categories (GluN2A/B-like and GluN2C/D-like) when considering voltage-dependent block by Mg2+, permeability to Ca2+ and unitary conductance.CC BY · PubMed Central
Fig. 2 Structure of ionotropic glutamate receptors. (a) Upper panel, linear representation of iGluR subunit highlighting the four functional domains; lower panel, schematic of the general structure of an iGluR subunit indicating the extracellularly located amino terminal domain (ATD) and ligand-binding domain (LBD) the transmembrane domain (TMD) comprised of three membrane-spanning helices (M1, M3 and M4) together with the re-entrant P-loop region of M2 and the large intracellularly located C-terminal domain (CTD). (b) Ribbon structure representation of the rat GluA2 homomeric AMPAR with each of the four subunits coloured coded and indicating the two conformationally distinct pairs of subunits, A/C and B/D. (c) model of the overall architecture of the NMDAR based on the GluA2 crystal structures of the ATD and TMD and the GluN1-GluN2A LBD heterodimer crystal structure. Panels (b) and (c) adapted from Sobolevsky et al. (2009). Copyright © 2009 Nature Publishing Group. Used with permission.
Fig. 2 Structure of ionotropic glutamate receptors. (a) Upper panel, linear representation of iGluR subunit highlighting the four functional domains; lower panel, schematic of the general structure of an iGluR subunit indicating the extracellularly located amino terminal domain (ATD) and ligand-binding domain (LBD) the transmembrane domain (TMD) comprised of three membrane-spanning helices (M1, M3 and M4) together with the re-entrant P-loop region of M2 and the large intracellularly located C-terminal domain (CTD). (b) Ribbon structure representation of the rat GluA2 homomeric AMPAR with each of the four subunits coloured coded and indicating the two conformationally distinct pairs of subunits, A/C and B/D. (c) model of the overall architecture of the NMDAR based on the GluA2 crystal structures of the ATD and TMD and the GluN1-GluN2A LBD heterodimer crystal structure. Panels (b) and (c) adapted from Sobolevsky et al. (2009). Copyright © 2009 Nature Publishing Group. Used with permission.CC BY · PubMed Central
Fig. 3 The Ser/Leu site in M3 controls NMDAR single-channel conductance (γ) and voltage-dependent block by Mg2+. (a) The characteristic high (∼50 pS) conductance of GluN1/GluN2A NMDARs is changed to a GluN1/GluN2D-like conduction by the point mutation GluN2A(S632L). (b) The reciprocal mutation in GluN2D that replaces the leucine residue at position 657 by serine gives rise to single-channel currents with a GluN1/GluN2A-like conductance. (c) The IC50 values for voltage-dependent Mg2+-block for GluN1/GluN2A(S632L) are comparable to those for GluN1/GluN2D NMDARs while IC50 values for GluN1/GluN2D(L657S) resemble those for GluN1/GluN2A NMDARs. Panels (a)-(c) from Siegler Retchless et al. (2012). Copyright © 2012 Nature Publishing Group. Used with permission.
Fig. 3 The Ser/Leu site in M3 controls NMDAR single-channel conductance (γ) and voltage-dependent block by Mg2+. (a) The characteristic high (∼50 pS) conductance of GluN1/GluN2A NMDARs is changed to a GluN1/GluN2D-like conduction by the point mutation GluN2A(S632L). (b) The reciprocal mutation in GluN2D that replaces the leucine residue at position 657 by serine gives rise to single-channel currents with a GluN1/GluN2A-like conductance. (c) The IC50 values for voltage-dependent Mg2+-block for GluN1/GluN2A(S632L) are comparable to those for GluN1/GluN2D NMDARs while IC50 values for GluN1/GluN2D(L657S) resemble those for GluN1/GluN2A NMDARs. Panels (a)-(c) from Siegler Retchless et al. (2012). Copyright © 2012 Nature Publishing Group. Used with permission.CC BY · PubMed Central
Fig. 4 The single-channel characteristics of NMDARs are determined by the GluN2 subunit assembled within the receptor. Steady-state single-channel recordings from excised outside-out membrane patches isolated from HEK293 cells expressing either GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, or GluN1/GluN2D NMDARs. For each receptor combination the upper panel illustrates 20 s of activity while the lower panel shows a selected higher resolution 100 ms period of activity. For all recordings, channel activity was elicited by glutamate (1 mM) in the presence of glycine (0.05 mM) and performed at pH 8.0 in 0.5 mM Ca2+. Unpublished data, kindly provided by S. M. Dravid, K. Erreger, K. Ogden, K. M. Vance, and S. F. Traynelis.
Fig. 4 The single-channel characteristics of NMDARs are determined by the GluN2 subunit assembled within the receptor. Steady-state single-channel recordings from excised outside-out membrane patches isolated from HEK293 cells expressing either GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, or GluN1/GluN2D NMDARs. For each receptor combination the upper panel illustrates 20 s of activity while the lower panel shows a selected higher resolution 100 ms period of activity. For all recordings, channel activity was elicited by glutamate (1 mM) in the presence of glycine (0.05 mM) and performed at pH 8.0 in 0.5 mM Ca2+. Unpublished data, kindly provided by S. M. Dravid, K. Erreger, K. Ogden, K. M. Vance, and S. F. Traynelis.CC BY · PubMed Central
Fig. 5 Control of NMDAR deactivation rates. (a) Example of a burst of openings arising from an activation of a wild-type (WT) GluN1/GluN2D NMDAR (ai. upper panel, grey); lower three traces (black) show examples of single activations of GluN1/GluN2D(T692A) NMDARs. For each the line denotes the period between the first opening and last closing of each burst. Comparison of burst length distributions (aii) for GluN1/GluN2D(T692) and WT GluN1/GluN2D NMDARs (shown as a dashed grey line). Note the numbering used to indicate the position of the threonine residue in GluN2D is for the mature protein (i.e. it excludes the signal peptide). (b) Representative whole-cell currents recorded from an HEK293 cell expressing GluN1/GluN2D NMDARs (bi) or GluN1/GluN2D NMDARs in which the ATD was removed (bii). Note the increase in the deactivation rate when the GluN2D ATD is absent. (c) Exon-5 lacking GluN1-1a subunits (ci) when co-expressed with GluN2D form NMDARs with typical slow deactivation rates, whereas GluN1-1b subunits which containing exon 5 (cii) accelerate deactivation of GluN2D-containing NMDARs. Panel (a) from Chen et al. (2004); (b) from Yuan et al. (2009) and (c) from Vance et al. (2012). Used with permission.
Fig. 5 Control of NMDAR deactivation rates. (a) Example of a burst of openings arising from an activation of a wild-type (WT) GluN1/GluN2D NMDAR (ai. upper panel, grey); lower three traces (black) show examples of single activations of GluN1/GluN2D(T692A) NMDARs. For each the line denotes the period between the first opening and last closing of each burst. Comparison of burst length distributions (aii) for GluN1/GluN2D(T692) and WT GluN1/GluN2D NMDARs (shown as a dashed grey line). Note the numbering used to indicate the position of the threonine residue in GluN2D is for the mature protein (i.e. it excludes the signal peptide). (b) Representative whole-cell currents recorded from an HEK293 cell expressing GluN1/GluN2D NMDARs (bi) or GluN1/GluN2D NMDARs in which the ATD was removed (bii). Note the increase in the deactivation rate when the GluN2D ATD is absent. (c) Exon-5 lacking GluN1-1a subunits (ci) when co-expressed with GluN2D form NMDARs with typical slow deactivation rates, whereas GluN1-1b subunits which containing exon 5 (cii) accelerate deactivation of GluN2D-containing NMDARs. Panel (a) from Chen et al. (2004); (b) from Yuan et al. (2009) and (c) from Vance et al. (2012). Used with permission.CC BY · PubMed Central
Fig. 6 Antagonism of NMDAR-mediated currents by TCN 201. (a) Left, example steady-state whole-cell NMDAR-mediated currents recorded from cortical pyramidal cells from (ai), days in vitro (DIV) 9–10 neurones, (aii), DIV 9–10 neurones transfected with GluN2A NMDAR subunits, and (aiii), DIV 15–18 neurones. To the right, traces illustrate the sensitivity of each of these NMDAR-mediated currents to the GluN2B-selective antagonist, ifenprodil and the subsequent sensitivity of the ifenprodil-insensitive component of this current to TCN 201. (b) Plot illustrating the extent of ifenprodil and TCN 201 antagonism of NMDA-evoked currents. Despite a wide range in the amount of block produced by either ifenprodil or TCN 201 the data show a strong (negative) correlation. (c) Equivalent plot to that illustrated in (b) but for antagonism by ifenprodil and TCN 213. Panels (a) and (b) from Edman et al. (2012) and (c) from McKay et al. (2012). Used with permission.
Fig. 6 Antagonism of NMDAR-mediated currents by TCN 201. (a) Left, example steady-state whole-cell NMDAR-mediated currents recorded from cortical pyramidal cells from (ai), days in vitro (DIV) 9–10 neurones, (aii), DIV 9–10 neurones transfected with GluN2A NMDAR subunits, and (aiii), DIV 15–18 neurones. To the right, traces illustrate the sensitivity of each of these NMDAR-mediated currents to the GluN2B-selective antagonist, ifenprodil and the subsequent sensitivity of the ifenprodil-insensitive component of this current to TCN 201. (b) Plot illustrating the extent of ifenprodil and TCN 201 antagonism of NMDA-evoked currents. Despite a wide range in the amount of block produced by either ifenprodil or TCN 201 the data show a strong (negative) correlation. (c) Equivalent plot to that illustrated in (b) but for antagonism by ifenprodil and TCN 213. Panels (a) and (b) from Edman et al. (2012) and (c) from McKay et al. (2012). Used with permission.CC BY · PubMed Central
Fig. 7 The identity of the GluN2 CTD determines the response to excitotoxic insult. (a) Cartoon depiction illustrating the C-terminal replacement (CTR) of the GluN2B CTD with that from GluN2A and denoted as GluN2B2A(CTR). (b) Quantification of hippocampal lesion volumes 24 h after stereotaxic injection of phosphate buffered saline (PBS) or 15 nmol of NMDA into the hippocampi of either GluN2B+/+ or GluN2B2A(CTR)/2A(CTR) mice. Note the significant reduction in lesion volumes when the GluN2B CTD is replaced by that of GluN2A. (c) Upper panels, representative pictures of haematoxylin and eosin-stained hippocampal sections showing the extent of NMDA-induced damage (dashed lines); lower panels, higher magnification of the boxed areas shown in the upper panels. Calibration bars in upper and lower panels are 250 μm and 50 μm, respectively. Panels (b) and (c) from Martel et al. (2012). Copyright © 2012 Cell Press. Used with permission.
Fig. 7 The identity of the GluN2 CTD determines the response to excitotoxic insult. (a) Cartoon depiction illustrating the C-terminal replacement (CTR) of the GluN2B CTD with that from GluN2A and denoted as GluN2B2A(CTR). (b) Quantification of hippocampal lesion volumes 24 h after stereotaxic injection of phosphate buffered saline (PBS) or 15 nmol of NMDA into the hippocampi of either GluN2B+/+ or GluN2B2A(CTR)/2A(CTR) mice. Note the significant reduction in lesion volumes when the GluN2B CTD is replaced by that of GluN2A. (c) Upper panels, representative pictures of haematoxylin and eosin-stained hippocampal sections showing the extent of NMDA-induced damage (dashed lines); lower panels, higher magnification of the boxed areas shown in the upper panels. Calibration bars in upper and lower panels are 250 μm and 50 μm, respectively. Panels (b) and (c) from Martel et al. (2012). Copyright © 2012 Cell Press. Used with permission.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 161 references

Cited by

Sorted by citations

See all 263

Related

Metadata

Authors
Wyllie, D. J. A., Livesey, M. R., & Hardingham, G. E.
Affiliations
University of Edinburgh (GB)
Corresponding author
Wyllie, D.J.A.
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2013-11
Volume
74
Pages
4-17
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2013.01.016
PMC
PMC3778433
OpenAlex
W2108909652
Cited by
260
References
161
Citations by year
2026: 6 · 2025: 27 · 2024: 21 · 2023: 16 · 2022: 29 · 2021: 24 · 2020: 20 · 2019: 23 · 2018: 26 · 2017: 18 · 2016: 18 · 2015: 16 · 2014: 10 · 2013: 5
FWCI
1.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • The Wellcome Trust
  • The Medical Research Council
  • The Biotechnology and Biological Science Research Council
  • The European Union
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
NMDA receptor, GluN2 subunits, receptor heterogeneity, ionotropic glutamate receptors, receptor subtypes, long-term potentiation, long-term depression, synaptic plasticity, fusion protein, receptor pharmacology, glutamate signalling
MeSH terms
Animals, Models, Molecular, Neuronal Plasticity, Receptors, N-Methyl-D-Aspartate, Long-Term Potentiation, Excitatory Amino Acid Antagonists, Protein Subunits, Protein Multimerization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review